Clinical pharmacology review of safinamide for the treatment of Parkinson's disease

Neurodegenerative disease management

Volumn 5, Issue 6, 2015, Pages 481-496

  Fabbri, Margherita ^a   Rosa, Mario M ^a   Abreu, Daisy ^a   Ferreira, Joaquim J ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

advanced Parkinson's disease; MAO B inhibitor; Parkinson's disease; safinamide

Indexed keywords

ALANINE; ANTIPARKINSON AGENT; BENZYLAMINE DERIVATIVE; SAFINAMIDE;

ANALOGS AND DERIVATIVES; ANIMAL; CHEMICAL STRUCTURE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; HUMAN; PARKINSON DISEASE;

ALANINE; ANIMALS; ANTIPARKINSON AGENTS; BENZYLAMINES; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; HUMANS; MOLECULAR STRUCTURE; PARKINSON DISEASE;

EID: 85050579297     PISSN: None     EISSN: 17582032     Source Type: Journal    
DOI: 10.2217/nmt.15.46     Document Type: Review

References (0)